Atrial Fibrillation – Epidemiology – Europe Data
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each country, as well as annualized case counts projected to the national population. Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years and the patient populations in the other countries under study over 10 years. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities are also forecast across the major pharmaceutical markets.
Clarivate Epidemiology’s AF forecast answers the following questions:
- How will change in the levels of exposure to known risk or protective factors affect the number of people living with AF?
- Of all people with AF, how many in each country have been formally diagnosed?
- Of all people diagnosed with AF, how many in the mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least twenty years of forecast data for the following AF patient populations:
- Total AF prevalent cases.
- Diagnosed AF prevalent cases.
- Undiagnosed AF prevalent cases.
- Diagnosed AF prevalent cases by subtype scheme.
- Diagnosed AF prevalent cases by hypertension status.
- Diagnosed AF prevalent cases by valvular heart disease status.
- Diagnosed AF prevalent cases by heart failure status.
- Diagnosed AF prevalent cases by CHADS2 score scheme.
- Diagnosed AF drug-treated prevalent cases.
- Diagnosed AF non-drug-treated prevalent cases.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Atrial Fibrillation - Epidemiology - Europe Data
- Introduction
- Key Findings
- Diagnosed Prevalence of Atrial Fibrillation per 1000 Among People Aged 40+ in 2021 and 2041
- Diagnosed Prevalence of Atrial Fibrillation per 1000 Among People Aged 40+ in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Atrial Fibrillation over the Next 20 years
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Atrial Fibrillation over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 by Disease Subtype
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 by Disease Subtype
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Heart Failure
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Heart Failure
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Hypertension
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Hypertension
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Valvular Heart Disease
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Valvular Heart Disease
- Number of Additional Prevalent Cases of Atrial Fibrillation in 2041 Across the Countries Under Study Due to Trends in Obesity
- Number of Additional Prevalent Cases of Atrial Fibrillation in 2041 Across the Countries Under Study Due to Trends in Obesity
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.